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Abstract
Aim: To recognize genetic associations of hydrochlorothiazide-induced change 
in serum uric acid (SUA) concentration. Patients & methods: We conducted a 
genome-wide association study on hydrochlorothiazide-induced change in SUA 
in 214 Finnish men from the GENRES study. Replication analyses were 
performed in 465 Finns from the LIFE study. Results: In GENRES, we 
identified 31 loci associated with hydrochlorothiazide-induced change in SUA 
at p  <  5  ×  10-5. rs1002976 near VEGFC associated with the change in 
GENRES and in LIFE. rs950569 near BRINP3 associated with the change in 
SUA in GENRES and LIFE. The analysis of previously reported SNPs and 
candidate genes provided some proof for PADI4 and ABCC4. Conclusion: We 
report genetic markers that may predict the increase in SUA concentration 
during thiazide treatment.
Keywords:
hydrochlorothiazide • pharmacogenomics • uric acid
Uric acid is the end product of endogenously produced and ingested purines in humans. Association of serum 
uric acid concentration with cardiovascular events has been demonstrated in numerous studies [1,2]. 
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Pharmacological lowering of serum uric acid concentrations in hypertensive older adults with xanthine oxidase 
inhibitor allopurinol may lower blood pressure (BP) [3] and decrease risk of stroke and myocardial infarction [4]. 
However, in some other studies, allopurinol has not had favorable effect on cardiovascular outcomes [5,6].
Increase in serum uric acid concentration is a common side effect of thiazide diuretic treatment, and the 
utmost manifestation of this side effect is provocation of symptomatic gout [7]. The increase may be caused by 
volume depletion [8], increased tubular reuptake of uric acid through SLC22A11 [9] and reduced ABCC4-
mediated secretion of uric acid in urine [10].
Large genome-wide studies have identified several genetic loci associated with serum uric acid concentrations 
[11] but only one genome-wide study on the effect of thiazide diuretics on serum uric acid concentration has been 
published [12]. This prompted us to conduct a genome-wide association study (GWAS) on the effect of 
hydrochlorothiazide (HCTZ) monotherapy on serum uric acid concentrations in the pharmacogenetic Genetics of 
Drug Responsiveness in Essential Hypertension (GENRES) study. Replication analysis of the most significant 




The design and accomplishment of the discovery study, GENRES, have been described previously [13]. Briefly, 
the GENRES study is a randomized, double-blind, placebo-controlled, cross-over study with four different 
antihypertensive monotherapies. All 4-week antihypertensive treatment periods were preceded by 4-week 
placebo periods (Supplementary Figure 1). The study drugs were HCTZ 25 mg, bisoprolol 5 mg, losartan 50 mg 
and amlodipine 5 mg, all once daily. Serum samples were drawn after each treatment and placebo period. The 
study subjects were 35- to 60-year-old Finnish men with hypertension and no significant comorbidities [13]. For 
the current study, we selected 214 subjects whose serum samples from at least one placebo period and from the 
HCTZ treatment period were available, and who were successfully genotyped (see below). The flowchart of the 
selection of the subjects for the present study is illustrated in Supplementary Figure 2. No episodes of gout 
emerged during the study.
The design of the replication study, LIFE, has been described previously [14]. The LIFE study is a randomized, 
double-blind study performed in Denmark, Finland, Norway, Sweden, UK and USA. Inclusion criteria were age of 
55 to 80  years, office systolic BP 160–200  mmHg or diastolic BP 95–115  mmHg, and signs of left ventricular 
hypertrophy in electrocardiography. Patients with following conditions were excluded: secondary hypertension, 
myocardial infarction or stroke within the preceding 6 months, beta-blocker- or calcium-antagonist-treated angina 
pectoris, heart failure, ejection fraction less than 40%, or other diseases treated with beta-blockers, angiotensin II 
type 1 receptor antagonists, thiazides or angiotensin-converting enzyme inhibitors. Patients were randomly 
assigned to treatment with losartan (50 mg daily) or atenolol (50 mg daily) after a 2-week placebo period. HCTZ 
12.5 mg daily was then added to the treatment if target BP, less than 140/90 mmHg, was not achieved. Later 
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treatment escalations included increase of the study drug dose to 100 mg, increase of HCTZ dose to 25 mg and 
addition of other antihypertensive drugs. However, only subjects using 12.5 mg of HCTZ were included in the 
present study (see below).
Total number of patients in the LIFE study was 9193 [14]. A pharmacogenetic substudy was done in 3503 
Scandinavian patients [15]. They included 1146 Finnish patients whose samples were available for GWAS [16]. In 
order to qualify into the replication analysis, the LIFE patients were required to be screened for serum uric acid 
level at the commencement of the study and 1 year after, and antihypertensive drug treatments needed to be 
intensified with a thiazide during the first year of the study to reach the BP targets; no patients were on HCTZ 
monotherapy. Accordingly, we chose patients using treatment of the first two titration steps (12.5 mg of HCTZ 
with 50 or 100 mg of the study drugs losartan/atenolol) at year 1 of the study. Initially, there were 557 patients 
with such treatment. We excluded 33 patients due to low success rate in genotyping, ambiguity in gender check 
or first-degree relativeness, 40 patients due to missing serum uric acid values at baseline or year 1, eight patients 
with chronic kidney disease (creatinine clearance <30 ml/min/1.73 m2 or urine microalbumin >300 mg/l), eight 
patients with morbid obesity (body mass index >40  kg/m2), and three patients with change in serum uric acid 
concentration deviating more than four SDs from the mean. [Query-Q5: Shikhil Vyas(CE) to All(AU)] Please define the following term: 
'SD'.  The flowchart of the selection of the subjects for the present study is illustrated in Supplementary Figure 3. 
The resulting 465 Finnish LIFE patients included in the replication analyses are listed according to their type of 
LIFE study treatment in Supplementary Table 1. The type of study treatment was included as covariate in the 
replication analyses as described in ‘Statistical analysis’.
Measurement of serum uric acid concentration
The serum samples of the GENRES study were stored at -80°C. Serum uric acid concentrations were measured 
in 2013, in other words, 9 years after the end of the clinical study (2004) in a single batch in the clinical laboratory 
of the Helsinki University Hospital using an enzymatic photometric method. It is possible that serum samples of a 
portion of subjects were thawed temporarily during the storage due to freezer failure. Therefore, we compared the 
serum uric acid results from the single-batch analysis with results from freshly-analyzed unfrozen serum samples 
drawn after the first placebo period. Pearson correlation coefficient between the two results was 0.98 and the 
corresponding Cronbach’s alpha 0.99, which indicates excellent reproducibility and therefore demonstrates the 
appropriateness of all long-term frozen samples for the present study.
Serum uric acid concentrations in the LIFE subjects were measured using PAP uricase method on 
DAX96analyzer (Hitachi 717 analyzer, Boehringer Mannheim, Mannheim, Germany).
Genotyping
The DNA samples of the GENRES study were genotyped using Illumina HumanOmniExpress-12 BeadChip 
(Illumina, Inc., CA, USA) at the Institute for Molecular Medicine Finland, University of Helsinki as described 
previously [17]. For the analysis of the most relevant SNPs of the earlier study of Vandell et al. [12], four SNPs 
were imputed in GENRES using IMPUTE2 (version 2.2.2) and the HapMap release 22.
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The samples of the 1146 LIFE study patients were genotyped using the same Illumina HumanOmniExpress 
BeadChip (Illumina) at the Institute for Molecular Medicine Finland, University of Helsinki as described previously 
[16]. Individual samples were discarded due to low success rate (<95%) or gender ambiguity (see above).
Statistical analysis
For genome-wide association analysis of HCTZ-induced change in serum uric acid concentration in GENRES, we 
generated residuals using stepwise linear regression in IBM SPSS Statistics program (version 22.0, SPSS, Inc., 
IL, USA). We calculated the concentration change as the value after HCTZ treatment minus the mean value after 
all placebo periods. Four placebo values were available for 187, three for 22, two for two and one for three 
subjects. Using stepwise linear regression with p < 0.10 as an inclusion criterion, we included baseline serum uric 
acid concentration (p  =  0.03) and current smoking (p  =  0.09) as covariates for the calculation of residuals 
(Supplementary Table 2). Covariates tested but not included (p  >  0.10) were age, duration of hypertension 
(years), serum creatinine concentration, creatinine clearance/1.73  m2; and body mass index. We used PLINK 
v.1.07 under an additive genetic model for the genome-wide association analysis [18]. We excluded SNPs with 
minor allele frequency <0.01 or Hardy–Weinberg equilibrium p < 1 × 10-5 from the analyses.
From the genome-wide association analysis of GENRES, we selected SNPs with p < 5 × 10-5 (representing 31 
loci) for replication analysis in Finnish LIFE patients. We calculated residuals for the change in serum uric acid 
concentration at year 1 of the study using linear regression and the following covariates: gender, treatment arm, 
baseline serum uric acid concentration and age (Supplementary Table 3). We used PLINK and additive genetic 
model for the replication analyses. We defined successful replication as Bonferroni-corrected p-value of 0.0016 
( = 0.05/31) and the same direction of effect as observed in GENRES. The data are presented as mean ± SD 
unless otherwise indicated. Because the study subjects of the discovery cohort (GENRES) were all men, a 
separate association analysis was performed in men in LIFE if SNP-by-sex interaction was significant (p < 0.05).
We used a SNP set-based method in GENRES to test the association of candidate genes (SLC22A11 and 
ABCC4) with HCTZ-induced elevation of serum uric acid. We included all successfully genotyped SNPs located 
within 100 kb of the genes (40 SNPs for SLC22A11 and 447 for ABCC4). For the analysis, we used PLINK with 
additive genetic model and residuals of HCTZ-induced change in serum uric acid, generated as described above. 
Single SNP was included if p-value was <0.05 and r2 with other included SNPs was <0.5. The maximum number 
of included SNPs was limited to five for each gene. For determination of empirical p-value, the data was permuted 
10,000-times for each gene.
Results
Study subjects
The baseline characteristics of the subjects included in the current study are presented in Table 1. Mean baseline 
serum uric acid concentrations of the GENRES and LIFE patients were similar, 357 and 335 μmol/l, respectively. 
Compared with GENRES, the patients of the LIFE study were older, had higher systolic BP, included also women 
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(54%) and fewer of them were current smokers. [Query-Q6: Shikhil Vyas(CE) to All(AU)] Please check and confirm that any figures/tables 
that appear in the article have been redrawn correctly, and if not, please describe any corrections that need to be made.
Table 1. Baseline data of the study subjects.
  [Query-Q7: Shikhil Vyas(CE) to All(AU)] Please provide column head here. GENRES LIFE
Number of subjects 214 465
Men (n/%) 214/100 216/46
Age (years) 50.5 (6.4) 64.0 (6.4)
Body mass index (kg/m2) 26.6 (2.8) 28.1 (3.7)
Baseline serum uric acid (μmol/l) 357 (59) 335 (68)
Hyperuricemic before study  (n/%) 2/1 29/6
Office systolic BP (mmHg) 152 (13) 172 (13)
Office diastolic BP (mmHg) 100 (6.7) 99 (7.7)
Current smokers (n/%) 36/17 55/12
Serum creatinine (μmol/l) 86 (13) 80 (13)
Serum glucose (mmol/l) 5.4 (0.6) 5.6 (1.4)
Data are presented as mean (standard deviation).
Serum uric acid >480 μmol/l in men and >400 μmol/l in women over 50 years of age.
p < 0.05 between GENRES and LIFE, analyzed with Student’s t-test for linear variables and with Fisher’s exact test for 
categorical variables.
BP: Blood pressure.
Effect of HCTZ on serum uric acid
During the 4-week monotherapy with 25  mg of HCTZ in GENRES, the mean increase of serum uric acid 
concentration was 50  ±  39  μmol/l (p  =  4.6  ×  10-47 in paired t-test; Supplementary Table 4). For comparison, 
losartan and amlodipine caused decreases (28 and 22  μmol/l, respectively) of serum uric acid level, while 
bisoprolol treatment increased serum uric acid level slightly (Supplementary Table 4).
In LIFE, an increase (49 ± 60 μmol/l) of serum uric acid level was seen in patients treated with atenolol (50 or 
100 mg) and HCTZ 12.5 mg at year 1 of the study (p = 1.0 × 10-26 in paired t-test) (Supplementary Table 1). In 
LIFE patients treated with losartan (50 or 100 mg) and HCTZ 12.5 mg, serum uric acid concentration increased 
nonsignificantly (5.4 ± 55 μmol/l; p = 0.13).
Genome-wide association analysis of HCTZ-induced change in serum uric acid in GENRES
The quantile–quantile plot of the genome-wide association analysis of HCTZ-induced change in serum uric acid 
concentration in GENRES (Supplementary Fig. 4) shows little evidence for genomic inflation and provides some 
support for the existence of significant associations. The Manhattan plot of the analysis indicates some potentially 
interesting signals although no SNP reached genome-wide significance (p < 5 × 10-8) (Figure 1). The lowest p-
value was obtained for rs2884594 on chromosome 12 near FGF23 (Supplementary Table 5). The 31 loci with p 
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Figure 1. XXX [Query-Q8: Shikhil Vyas(CE) to All(AU)] Please provide a general/main title for Figure 1.
Replication analysis in LIFE
The replication analyses of the 31 most significant loci in GENRES carried out in LIFE subjects treated with HCTZ 
(and 50 or 100 mg of atenolol or losartan) are summarized in detail in Supplementary Table 5. The lowest p-value 
(p = 3.6 × 10-4) was obtained for rs1002976 on chromosome 4 near VEGFC, reaching the Bonferroni-corrected 
significance level (p < 1.6 × 10-3). rs950569 on chromosome 1 near BRINP3 was also associated with change in 
serum uric acid concentration in LIFE with a p-value of 2.6  ×  10-3, almost reaching the Bonferroni-corrected 
significance level (Supplementary Table 5). In contrast, rs2884594 near FGF23 associated with the lowest p-
value in GENRES did not replicate in LIFE (p = 0.32). However, rs11612082 which is in linkage disequilibrium 
(LD) with rs2884594 (r2  =  0.66 in 1000 Genomes Finns) showed a trend for replication (p  =  2.0  ×  10-5 in 
GENRES; p = 0.084 in LIFE). SNP-by-sex interaction analysis of the 31 most significant loci in GENRES was 
carried out in LIFE (Supplementary Table 5). The interaction was significant for one SNP, rs508362 in RREB1. 
The p-value for the association of serum uric acid change with this SNP was somewhat stronger in men 
(beta = 19.2 μmol/l; p = 0.07) than in men and women combined (beta = 4.6 μmol/l; p = 0.5).
Regional Manhattan plots for the two loci with the most consistent replication data are illustrated in Figures 2 
and 3. rs1002976 is located approximately 27  kb downstream of VEGFC, while rs950569 is located 226  kb 
downstream of BRINP3.
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Figure 2. XXX [Query-Q9: Shikhil Vyas(CE) to All(AU)] Please provide a general/main title for Figure 2.
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Figure 3. XXX [Query-Q10: Shikhil Vyas(CE) to All(AU)] Please provide a general/main title for Figure 3.
Associations of rs1002976 and rs950569 genotypes with HCTZ-induced changes in serum uric acid 
concentration in GENRES and LIFE are illustrated in Figures 4 and 5. In both cases, a significant gene-dosage 
type of effect was observed upon genotype comparisons. Cluster plots of genotyping of rs1002976 and rs950569 
are presented in Supplementary Figure 5. [Query-Q11: Bethany Lucey(PE) to All(AU)] Please could you let me know if you would like your 
figures printed in colour? The cost of colour printing is UK£155 per figure, with a discount for articles with two or more figures. Thus, the price to print all your 
figures in colour is £535.
Figure 4. XXX [Query-Q12: Shikhil Vyas(CE) to All(AU)] Please provide a general/main title for Figure 4.
 HCTZ: Hydrochlorothiazide.
 
Figure 5. XXX [Query-Q13: Shikhil Vyas(CE) to All(AU)] Please provide a general/main title for Figure 5.
 HCTZ: Hydrochlorothiazide.
 
Analysis of the most significant results derived from an earlier GWAS
In an earlier GWAS study [12], altogether six SNPs, one in Caucasians and five in African Americans, were 
associated with HCTZ-induced change in serum uric acid concentration. Among those reported in African 
Americans (Supplementary Table 6), rs2477134 showed some evidence of association in GENRES (beta  = 
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-9.3  μmol/l; p  =  0.016). rs2477134 is located on chromosome 1 near PADI4. The SNP rs1418243 reported 
positive for Caucasians did not replicate in our study (Supplementary Table 6).
Analysis of the association of candidate genes with HCTZ-induced elevation of serum uric acid
In the SNP set-based test for ABCC4 in GENRES, the combined p-value for the five most significant SNPs was 
0.055 (Supplementary Table 7). The top SNP (rs9561863; p = 5.6 × 10-4) is located 74 kb upstream from ABCC4. 
The other four SNPs are intronic. Within 100 kb of SLC22A11 no SNP was associated with uric acid change with 
p < 0.05.
Discussion
In the current study, we searched for SNPs associated with HCTZ-induced increase in serum uric acid 
concentration. In the genome-wide analysis of the discovery cohort (GENRES), no SNP reached genome-wide 
significance but 31 potential loci of interest (p < 5 × 10-5) were identified. Using the replication cohort (the Finnish 
subjects of the LIFE study), we obtained support for two of these loci. In addition, analysis of results from an 
earlier study [12] as well as SNP set-based analysis of two candidate genes provided potentially significant 
results. The SNPs showing the strongest association with serum uric acid level in our study had effect sizes of ca. 
10–20  μmol/l per allele. Whether this magnitude reflects clinical significance is presently unknown, but it is of 
interest that an increase of 60 μmol/l in serum uric acid concentration has been proposed to associate with a 15% 
increased risk of total and cardiovascular mortality [19,20].
We consider the association of rs1002976 with change in serum uric acid during HCTZ treatment as the most 
significant finding of the present study. The association was observed both in the GENRES discovery cohort 
(beta = -16 μmol/l; p = 2 × 10-5) and in the Finnish LIFE replication cohort (beta = -14 μmol/l; p = 4 × 10-4) (Figure 
4). rs1002976 is located on chromosome 4 at a distance of 56  kb from VEGFC, which codes for vascular 
endothelial growth factor C. The LD block of this SNP does not extend to the actual VEGFC area (Figure 2). 
[Query-Q14: Shikhil Vyas(CE) to All(AU)] Please define the following term: 'eQTL'. However, eQTL data [21,22] suggest that rs1002976 
may be associated with the expression level of VEGFC mRNA (p = 0.0055, adrenal gland) [], although rs1002976 
itself does not seem to cause any changes in regulatory DNA elements. VEGFC promotes lymphangiogenesis 
and angiogenesis by binding to VEGFR2 and VEGFR3 [23]. It induces proliferation and survival of endothelial 
cells [23], and its increased expression has been linked to production of proinflammatory cytokines [24]. 
Interestingly, thiazide diuretics and VEGFC were related in an earlier study where secretion of VEGFC protein in 
culture medium by vascular smooth muscle cells was reduced by chlorthalidone and bendroflumethiazide [25]. 
Regulation of uric acid has also been related to VEGF gene family in an earlier study: its serum levels associated 
with VEGFA SNPs in a large meta-analysis [11]. VEGFA and VEGFC share the same receptor, VEGFR2, which 
probably mediates most of the vascular effects of VEGFs [26].
rs950569 on chromosome 1 associated with change in serum uric acid in the GENRES discovery cohort 
(beta = 33 μmol/l; p = 5 × 10-5), while in the LIFE replication cohort the association (beta = 21 μmol/l; p = 0.003) 
did not quite meet the Bonferroni-corrected significance level (Figure 5). This SNP is located on an intergenic 
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area close to a lincRNA gene. The closest gene with known function is BRINP3 (Figure 3), which codes for 
protein ‘BMP/retinoid acid inducible neural specific 3’. BRINP3 is involved in the development and maintenance of 
nervous system [27,28]. BRINP3 may also be a marker of inflammation [28]. To our knowledge, BRINP3 has not 
earlier been associated with uric acid metabolism. In dbGaP, rs950569 is reported to associate with results from 
platelet function tests [29].
rs2884594 reached the most significant association in GENRES (beta = 20 μmol/l; p = 9.5 × 10-7). One SNP 
from the same locus was to some extent replicated in LIFE (Supplementary Table 5). The closest gene of this 
locus is FGF23, which codes for fibroblast growth factor 23. FGF23 is a regulator of kidney phosphate and 
vitamin D metabolism and it is produced mainly in bone [30]. Interestingly, serum FGF23 levels have been shown 
to associate with serum uric acid concentrations and uric acid clearance [31-33].
Six other SNPs previously associated with HCTZ-induced change in serum uric acid concentration were also 
tested in our study [12]. Some support for the association was obtained for rs2477134 in our GENRES study 
(Supplementary Table 6). This SNP is located 1  kb away from PADI4 on chromosome 1. PADI4 codes for 
peptidyl arginine deiminase 4, which catalyzes the deimination of arginine to citrulline. GTExportal.com database 
indicates that this SNP may be associated with expression level of PADI4 mRNA (p = 0.0006, lung) [21]. PADI4 
has previously been associated with rheumatoid arthritis and multiple sclerosis [34].
ABCC4 has been suggested to mediate the reduction of urinary uric acid secretion by HCTZ [10]. Some 
support for possible underlying genetic mechanisms was obtained in the SNP set-based analysis of ABCC4 
(±  100  kb) in GENRES (p  =  0.055) (Supplementary Table 7). There is scarce earlier data on ABCC4 genetic 
variation and metabolism of uric acid: rs12870204 (in LD with rs4148455, one of the five SNPs discovered in this 
study) was weakly associated with serum uric acid concentrations in subjects with normal kidney function [35].
The major strength of the present study lies in the careful design of the GENRES study: it was placebo-
controlled and the baseline estimates for serum uric acid concentration were derived from up to four placebo 
periods for each subject. In addition, any drug-related effects can be controlled for their specificity because four 
different antihypertensive classes were involved. The replication cohort was of the same ethnic background, and 
the same genotyping platforms were used in both cohorts. However, our study has some important limitations. 
First, the sample size of the discovery study (GENRES) was relatively small. Second, both men and women were 
included in LIFE, whereas GENRES consisted of men only. Third, due to study design, subjects of the Finnish 
LIFE replication study were unavoidably treated with a combination therapy also including atenolol or losartan, 
even if the treatment arm was included as a covariate in the analyses. Fourth, the 12.5-mg dose of HCTZ in the 
replication study was lower than the 25-mg dose in GENRES.
Conclusion
We have identified a few interesting SNPs that may predict the increase of serum uric acid concentration during 
HCTZ treatment. Additional studies in other and even larger populations are needed to confirm these data. 
However, it is not known if the associations translate into clinically significant differences, such as occurrence of 
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gout or cardiovascular events during thiazide treatment. [Query-Q15: Bethany Lucey(PE) to All(AU)] Table 2 is not cited in the text, 
please indicate where this citation should be inserted.
Table 2
Table 2. Summary of the most significant SNP associations of hydrochlorothiazide-induced increase in serum 
uric acid concentration.
SNP Closest gene Chr Position CA/NCA GENRES LIFE
          n CAF Beta p-value n CAF Beta p-value
rs1002976 VEGFC 4 177548598 A/G 214 0.47 -16.0 2.3 × 10-5 465 0.48 -13.7 3.6 × 10-4
rs950569 BRINP3 1 189841077 A/C 213 0.06 33.2 4.8 × 10-5 465 0.06 21.5 2.6 × 10-3




CA: Coded allele; CAF: Coded allele frequency; Chr: Chromosome; NCA: Noncoded allele.
Summary points
Background
Hyperuricemia is a common side effect of thiazide diuretics.
A genome-wide association study on the effect of hydrochlorothiazide on serum uric acid concentration 
was conducted in GENRES subjects and replication analysis of the best results was done in Finnish 
LIFE subjects.
Results
In GENRES, 31 potential genetic loci (p < 5 × 10-5) were identified.
rs1002976 near VEGFC was positively replicated in LIFE.
rs950569 near BRINP3 was replicated with borderline significance in LIFE.
Some additional support for previously reported rs2477134 near PADI4 was obtained in GENRES.
Conclusion
The present study revealed a few novel possible genetic markers of hydrochlorothiazide-induced 
change in serum uric acid concentration.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: 
 www.futuremedicine.com/doi/full/10.2217/pgs-2017-0184
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